Jennemann, R.; Volz, M.; Frias-Soler, R.C.; Schulze, A.; Richter, K.; Kaden, S.; Sandhoff, R.
Glucosylceramide Synthase Inhibition in Combination with Aripiprazole Sensitizes Hepatocellular Cancer Cells to Sorafenib and Doxorubicin. Int. J. Mol. Sci. 2025, 26, 304.
https://doi.org/10.3390/ijms26010304
AMA Style
Jennemann R, Volz M, Frias-Soler RC, Schulze A, Richter K, Kaden S, Sandhoff R.
Glucosylceramide Synthase Inhibition in Combination with Aripiprazole Sensitizes Hepatocellular Cancer Cells to Sorafenib and Doxorubicin. International Journal of Molecular Sciences. 2025; 26(1):304.
https://doi.org/10.3390/ijms26010304
Chicago/Turabian Style
Jennemann, Richard, Martina Volz, Roberto Carlos Frias-Soler, Almut Schulze, Karsten Richter, Sylvia Kaden, and Roger Sandhoff.
2025. "Glucosylceramide Synthase Inhibition in Combination with Aripiprazole Sensitizes Hepatocellular Cancer Cells to Sorafenib and Doxorubicin" International Journal of Molecular Sciences 26, no. 1: 304.
https://doi.org/10.3390/ijms26010304
APA Style
Jennemann, R., Volz, M., Frias-Soler, R. C., Schulze, A., Richter, K., Kaden, S., & Sandhoff, R.
(2025). Glucosylceramide Synthase Inhibition in Combination with Aripiprazole Sensitizes Hepatocellular Cancer Cells to Sorafenib and Doxorubicin. International Journal of Molecular Sciences, 26(1), 304.
https://doi.org/10.3390/ijms26010304